Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.36 |
| ▸ | TST | Q16762 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL30356570 | 0.98 | LMNA (0.68) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL31150443 | 0.98 | LMNA (0.68) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20788532 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21768341 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL5165448 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21645349 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20839746 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21815619 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20477191 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21330886 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3856257-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856255-A1 | TREATMENT OF INFECTIONS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164616-A | Degradable hyaluronic acid hydrogel | 阿森迪斯药物股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020064844-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020064847-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | LMNA 2801/4885MAPT 3817/4885L3MBTL1 4125/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | LMNA 306/4885MAPT 4452/4885L3MBTL1 287/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | LMNA 2251/4885MAPT 1853/4885L3MBTL1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.